{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:57:37Z","timestamp":1795089457546,"version":"4.10.2"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Toxoplasmosis in hematopoietic stem-cell transplant (HSCT) recipients can be life threatening if not promptly diagnosed and treated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We performed a systematic review (PubMed last search March 29, 2020) of toxoplasmosis among HSCT recipients and calculated the toxoplasmosis prevalence across studies. We also created a compilation list of brain imaging, chest imaging, and autopsy findings of toxoplasmosis among HSCT recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>We identified 46 eligible studies (47 datasets) with 399 toxoplasmosis cases among 38\u2009751 HSCT recipients. There was large heterogeneity in the reported toxoplasmosis prevalence across studies, thus formal meta-analysis was not attempted. The median toxoplasmosis prevalence among 38\u2009751 HSCT recipients was 2.14% (range 0%\u201366.67%). Data on toxoplasmosis among at-risk R<jats:sup>+<\/jats:sup>HSCT recipients were more limited (25 studies; 2404 R<jats:sup>+<\/jats:sup>HSCT recipients [6.2% of all HSCT recipients]), although the median number of R<jats:sup>+<\/jats:sup>HSCT recipients was 56.79% across all HSCT recipients. The median toxoplasmosis prevalence across studies among 2404 R<jats:sup>+<\/jats:sup>HSCT was 7.51% (range 0%\u201380%) versus 0% (range 0%\u20131.23%) among 7438 R<jats:sup>\u2013<\/jats:sup>HSCT. There were limited data to allow meaningful analyses of toxoplasmosis prevalence according to prophylaxis status of R<jats:sup>+<\/jats:sup>HSCT recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Toxoplasmosis prevalence among HSCT recipients is underestimated. The majority of studies report toxoplasmosis prevalence among all HSCT recipients rather than only among the at-risk R<jats:sup>+<\/jats:sup>HSCT recipients. In fact, the median toxoplasmosis prevalence among all R<jats:sup>+\/<\/jats:sup>\/R<jats:sup>\u2013<\/jats:sup> HSCT recipients is 3.5-fold lower compared with the prevalence among only the at-risk R<jats:sup>+<\/jats:sup>HSCT recipients and the median prevalence among R<jats:sup>+<\/jats:sup>HSCT recipients is 7.51-fold higher than among R<jats:sup>\u2013<\/jats:sup>HSCT recipients. The imaging findings of toxoplasmosis among HSCT recipients can be atypical. High index of suspicion is needed in R<jats:sup>+<\/jats:sup>HSCT recipients with fever, pneumonia, or encephalitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003662","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T09:52:29Z","timestamp":1614765149000},"page":"e375-e386","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Toxoplasmosis Among 38 751 Hematopoietic Stem-cell Transplant Recipients: A Systematic Review of Disease Prevalence and a Compilation of Imaging and Autopsy Findings"],"prefix":"10.1097","volume":"105","author":[{"given":"Despina G.","family":"Contopoulos-Ioannidis","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA."},{"name":"Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation, Palo Alto, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Cho","sequence":"additional","affiliation":[{"name":"Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bertaina","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology and Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann N.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Radiology, Thoracic Imaging, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Fischbein","sequence":"additional","affiliation":[{"name":"Department of Radiology, Neuroimaging and Neuro-intervention, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Lanzman","sequence":"additional","affiliation":[{"name":"Department of Radiology, Neuroimaging and Neuro-intervention, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden T.","family":"Schwenk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G.","family":"Montoya","sequence":"additional","affiliation":[{"name":"Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto Medical Foundation, Palo Alto, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1086\/317471","article-title":"Toxoplasmosis after hematopoietic stem cell transplantation.","volume":"31","author":"Martino","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3201\/eid2408.180045","article-title":"Toxoplasmosis in transplant recipients, Europe, 2010-2014.","volume":"24","author":"Robert-Gangneux","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QCO.0000000000000169","article-title":"Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations.","volume":"28","author":"Gajurel","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1086\/605433","article-title":"Risk factors for Toxoplasma gondii infection in the United States.","volume":"49","author":"Jones","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4269\/ajtmh.14-0013","article-title":"Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades.","volume":"90","author":"Jones","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4269\/ajtmh.17-0677","article-title":"Toxoplasma gondii Infection in the United States, 2011-2014.","volume":"98","author":"Jones","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41409-019-0641-y","article-title":"Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting.","volume":"55","author":"Paccoud","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1086\/426447","article-title":"Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation.","volume":"40","author":"Martino","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/595709","article-title":"Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques.","volume":"48","author":"Fricker-Hidalgo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0463.2008.00871.x","article-title":"A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation.","volume":"116","author":"Edvinsson","year":"2008","journal-title":"APMIS"},{"key":"R11-20250607","first-page":"24","article-title":"[Retrospective study of the implementation of the qualitative PCR technique in biological samples for monitoring toxoplasmosis in pediatric patients receiving hematopoietic stem cell transplantation].","volume":"46","author":"Nigro","year":"2014","journal-title":"Rev Argent Microbiol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/651266","article-title":"Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation.","volume":"50","author":"Meers","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R13-20250607","first-page":"9409121","article-title":"Toxoplasma encephalitis following tandem autologous hematopoietic stem cell transplantation: a case report and review of the literature.","volume":"2018","author":"Kollu","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MPH.0b013e3182677e84","article-title":"Cerebral toxoplasmosis after tandem high-dose chemotherapy and autologous hematopoietic cell transplant for neuroblastoma.","volume":"35","author":"Voegele","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14787210.2018.1483721","article-title":"Management of toxoplasmosis in transplant recipients: an update.","volume":"16","author":"Dard","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.bmt.1703425","article-title":"Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature.","volume":"29","author":"Mele","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/clinids\/15.2.267","article-title":"Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review.","volume":"15","author":"Derouin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/sj.bmt.1700736","article-title":"Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team.","volume":"19","author":"Chandrasekar","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jtct.2020.11.003","article-title":"Toxoplasmosis in Pediatric Hematopoietic Stem Cell Transplantation Patients.","volume":"27","author":"Schwenk","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pbc.21774","article-title":"Intermittent oral trimethoprim\/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation.","volume":"52","author":"Ohata","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"e13198","DOI":"10.1111\/tid.13198","article-title":"Failure of atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients.","volume":"22","author":"Chueng","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/tid.12532","article-title":"Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients.","volume":"18","author":"Gajurel","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/INF.0b013e3181f30eb6","article-title":"Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man.","volume":"29","author":"Garcia de la Fuente","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1399-3046.2007.00891.x","article-title":"Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation.","volume":"12","author":"Megged","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jpids\/piab006","article-title":"Response to Trimethoprim-Sulfamethoxazole in a Pediatric Hematopoietic Stem Cell Transplant Recipient With Disseminated Toxoplasmosis: A Case Report.","volume":"10","author":"Khan","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4322\/acr.2017.036","article-title":"Declining rate of autopsies: implications for anatomic pathology residents.","volume":"7","author":"Hamza","year":"2017","journal-title":"Autops Case Rep"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"e01223\u201319","DOI":"10.1128\/JCM.01223-19","article-title":"Is real-time PCR targeting Rep 529 suitable for diagnosis of toxoplasmosis in patients infected with non-type ii strains in North America?","volume":"58","author":"Pomares","year":"2020","journal-title":"J Clin Microbiol"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00007890-199803150-00001","article-title":"Organ donor screening for infectious diseases: review of practice and implications for transplantation.","volume":"65","author":"Delmonico","year":"1998","journal-title":"Transplantation"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/TP.0b013e318169bebd","article-title":"The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis.","volume":"85","author":"Gourishankar","year":"2008","journal-title":"Transplantation"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.TP.0000044864.99398.F1","article-title":"Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole.","volume":"75","author":"Baden","year":"2003","journal-title":"Transplantation"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1469-0691.2008.02091.x","article-title":"Prevention of toxoplasmosis in transplant patients.","volume":"14","author":"Derouin","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/bmt.2017.117","article-title":"Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists.","volume":"52","author":"Decembrino","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R34-20250607","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw330","article-title":"Implementation of molecular surveillance after a cluster of fatal toxoplasmosis at 2 neighboring transplant centers.","volume":"63","author":"Isa","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R35-20250607","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bmt.1702396","article-title":"Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.","volume":"25","author":"Martino","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R36-20250607","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12734","article-title":"Toxoplasmosis in hematopoietic cell transplant recipients.","volume":"19","author":"Gajurel","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"R37-20250607","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00277-012-1406-5","article-title":"Toxoplasmosis after allogeneic stem cell transplantation\u2013a single centre experience.","volume":"91","author":"Busemann","year":"2012","journal-title":"Ann Hematol"},{"key":"R38-20250607","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/JCM.03282-14","article-title":"Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study.","volume":"53","author":"Robert-Gangneux","year":"2015","journal-title":"J Clin Microbiol"},{"key":"R39-20250607","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/bmt.2010.102","article-title":"Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence.","volume":"46","author":"Mulanovich","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:12:38Z","timestamp":1749312758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003662","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}